{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T17:23:54Z","timestamp":1772299434163,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41417-025-00948-y","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T06:37:33Z","timestamp":1754116653000},"page":"1090-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-7797","authenticated-orcid":false,"given":"Claudia","family":"Guerrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Casal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Alierta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Moreo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3360-4479","authenticated-orcid":false,"given":"Miguel","family":"Araujo-Voces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7866-2803","authenticated-orcid":false,"given":"Santiago","family":"Uranga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9713-2127","authenticated-orcid":false,"given":"Ana Bel\u00e9n","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-5478","authenticated-orcid":false,"given":"Carlos","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-9173","authenticated-orcid":false,"given":"Nacho","family":"Aguil\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"948_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/BF00187656","volume":"6","author":"CJ Herold","year":"1996","unstructured":"Herold CJ, Bankier AA, Fleischmann D. Lung metastases. Eur Radio. 1996;6:596\u2013606.","journal-title":"Eur Radio"},{"key":"948_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A Lopez-Soto","year":"2017","unstructured":"Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32:135\u201354.","journal-title":"Cancer Cell"},{"key":"948_CR3","doi-asserted-by":"crossref","unstructured":"Chan IS, Ewald AJ. The changing role of natural killer cells in cancer metastasis. J Clin Invest. 2022;132.","DOI":"10.1172\/JCI143762"},{"key":"948_CR4","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1038\/onc.2009.117","volume":"28","author":"A Lopez-Soto","year":"2009","unstructured":"Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene. 2009;28:2370\u201382.","journal-title":"Oncogene"},{"key":"948_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DS, O\u2019Callaghan CA, Soderstrom K, D\u2019Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature. 1998;391:795\u20139.","journal-title":"Nature"},{"key":"948_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","volume":"127","author":"ED Carosella","year":"2015","unstructured":"Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. HLA-G: An Immune Checkpoint Molecule. Adv Immunol. 2015;127:33\u2013144.","journal-title":"Adv Immunol"},{"key":"948_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1593\/neo.121758","volume":"15","author":"A Bruno","year":"2013","unstructured":"Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia. 2013;15:133\u201342.","journal-title":"Neoplasia"},{"key":"948_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14677","volume":"8","author":"PM Tang","year":"2017","unstructured":"Tang PM, Zhou S, Meng XM, Wang QM, Li CJ, Lian GY, et al. Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. Nat Commun. 2017;8:14677.","journal-title":"Nat Commun"},{"key":"948_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H Li","year":"2009","unstructured":"Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240\u20139.","journal-title":"J Immunol"},{"key":"948_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/cmi.2013.2","volume":"10","author":"I Pedroza-Pacheco","year":"2013","unstructured":"Pedroza-Pacheco I, Madrigal A, Saudemont A. Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol. 2013;10:222\u20139.","journal-title":"Cell Mol Immunol"},{"key":"948_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1062968","volume":"5","author":"G Berchem","year":"2016","unstructured":"Berchem G, Noman MZ, Bosseler M, Paggetti J, Baconnais S, Le Cam E, et al. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-beta and miR23a transfer. Oncoimmunology. 2016;5:e1062968.","journal-title":"Oncoimmunology"},{"key":"948_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","volume":"4","author":"A Young","year":"2014","unstructured":"Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014;4:879\u201388.","journal-title":"Cancer Discov"},{"key":"948_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s43018-020-0068-9","volume":"1","author":"HC Lo","year":"2020","unstructured":"Lo HC, Xu Z, Kim IS, Pingel B, Aguirre S, Kodali S, et al. Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis. Nat Cancer. 2020;1:709\u201322.","journal-title":"Nat Cancer"},{"key":"948_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180\u20133.","journal-title":"J Urol"},{"key":"948_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41768-8","volume":"14","author":"E Moreo","year":"2023","unstructured":"Moreo E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, Guerrero C, Gomez AB, et al. Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung. Nat Commun. 2023;14:6090.","journal-title":"Nat Commun"},{"key":"948_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1258\/002367705774286475","volume":"39","author":"A Loskog","year":"2005","unstructured":"Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmstrom PU, Totterman TH. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim. 2005;39:384\u201393.","journal-title":"Lab Anim"},{"key":"948_CR17","doi-asserted-by":"publisher","first-page":"722.e1","DOI":"10.1016\/j.urology.2011.04.044","volume":"78","author":"X Zhang","year":"2011","unstructured":"Zhang X, Shi X, Li J, Hu Z, Guo F, Huang X, et al. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells. Urology. 2011;78:722.e1\u2013e6.","journal-title":"Urology"},{"key":"948_CR18","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.juro.2011.10.126","volume":"187","author":"X Zhang","year":"2012","unstructured":"Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J, et al. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J Urol. 2012;187:1071\u20139.","journal-title":"J Urol"},{"key":"948_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"948_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42:209\u201324.e9.","journal-title":"Cancer Cell"},{"key":"948_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","volume":"10","author":"R Bai","year":"2020","unstructured":"Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of Cancer Resistance to Immunotherapy. Front Oncol. 2020;10:1290.","journal-title":"Front Oncol"},{"key":"948_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41:272\u201387.e9.","journal-title":"Cancer Cell"},{"key":"948_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43790-2","volume":"14","author":"A Ramos","year":"2023","unstructured":"Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, et al. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening. Nat Commun. 2023;14:8048.","journal-title":"Nat Commun"},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall T, Andre P, Horowitz A, Ruan DF, Borst L, Zerbib R, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7:263.","journal-title":"J Immunother Cancer"},{"key":"948_CR25","first-page":"43","volume":"4","author":"J Qiu","year":"2023","unstructured":"Qiu J, Xu B, Ye D, Ren D, Wang S, Benci JL, et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat Cancer. 2023;4:43\u201361.","journal-title":"Nat Cancer"},{"key":"948_CR26","doi-asserted-by":"crossref","unstructured":"O\u2019Leary K. JAK inhibitor reinvigorates cancer immunotherapy. Nat Med. 2024.","DOI":"10.1038\/d41591-024-00053-x"},{"key":"948_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","volume":"384","author":"J Zak","year":"2024","unstructured":"Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384:eade8520.","journal-title":"Science"},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386:1973\u201385.","journal-title":"N Engl J Med"},{"key":"948_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S2468-1253(22)00083-8","volume":"7","author":"F Wei","year":"2022","unstructured":"Wei F. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2022;7:504.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00948-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00948-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00948-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:02:38Z","timestamp":1760911358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00948-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00948-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.09.617367","asserted-by":"object"}]},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}